[Spirometric values of asthmatic children treated with Plaferon-LB]

Area of Science:

• Pulmonology
• Pediatric Medicine
• Pharmacology

Background:

• Childhood asthma is a chronic respiratory condition requiring effective management.
• Traditional bronchodilators can have side effects, necessitating exploration of alternative therapies.

Purpose of the Study:

• To evaluate the efficacy of inhaled Plaferon LB in pediatric asthma patients.
• To compare Plaferon LB treatment with a placebo in a double-blind, controlled study.

Main Methods:

• A 3-week, double-blind, placebo-controlled study involving 43 children with asthma.
• Daily inhalations of standard-dose Plaferon LB (5 mg/ml - 3 ml) or placebo via nebulizer.
• Spirometric data collected weekly to assess lung function.

Main Results:

• Statistically significant improvements in spirometric values were observed in the Plaferon LB group.
• No adverse events were mentioned, suggesting a favorable safety profile.

Conclusions:

• Long-term Plaferon LB inhalation therapy is an effective treatment for childhood asthma.
• Plaferon LB presents a safe and viable alternative to conventional bronchodilator medications for pediatric asthma.